Matches in SemOpenAlex for { <https://semopenalex.org/work/W2017456906> ?p ?o ?g. }
- W2017456906 endingPage "826" @default.
- W2017456906 startingPage "821" @default.
- W2017456906 abstract "No AccessJournal of UrologyClinical Urology: Original Article1 Mar 1996Prostate Specific Antigen Detected Prostate Cancer (Clinical Stage T1C): An Interim Analysis Seth E. Lerner, Thomas M. Seay, Michael L. Blute, Erik J. Bergstralh, David Barrett, and Horst Zincke Seth E. LernerSeth E. Lerner Current address: Department of Urology, Albert Einstein College of Medicine, Montefiore Medical Center, 111 East 210th St., Bronx, New York 10467. More articles by this author , Thomas M. SeayThomas M. Seay More articles by this author , Michael L. BluteMichael L. Blute More articles by this author , Erik J. BergstralhErik J. Bergstralh More articles by this author , David BarrettDavid Barrett More articles by this author , and Horst ZinckeHorst Zincke More articles by this author View All Author Informationhttps://doi.org/10.1016/S0022-5347(01)66317-1AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: The majority of impalpable prostate cancers (stage T1c) are biologically significant. We report the interim results in 257 patients with stage T1c prostate cancer treated with radical prostatectomy. Materials and Methods: Prostate specific antigen progression-free survival was assessed by the Kaplan-Meier method. Multivariate analyses were performed to determine which clinical and pathological variables independently correlated with progression. Comparisons among the various clinical substages (T1a to T2b/c) were calculated. Results: Of the patients with stage T1c cancers 51 percent had stage pT2c or less and 91 percent had clinically significant tumors on the basis of pathological grade, deoxyribonucleic acid ploidy and tumor volume. High preoperative prostate specific antigen, poorly differentiated tumors and nondiploid status were strong independent predictors of progression. The 5-year survival rate free of progression was 84 percent. Patients with clinical stage T1c cancers had a significant progression-free survival advantage compared to those with clinical stage T2b/c disease (p = 0.0005). Conclusions: Impalpable tumors should not be regarded as insignificant or innocuous on the basis of pathological analysis. Disease-free survival in the stage T1c group was similar to that in the clinical stages T1a to T2a group but significantly better than that in the T2b/c group. References 1 : Cancer statistics, 1994. CA1994; 44: 7. Google Scholar 2 : Defining and updating the American Cancer Society guidelines for cancer-related checkup: prostate and endometrial cancers. CA1993; 43: 42. Google Scholar 3 : Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. New Engl. J. Med.1991; 324: 1156. Google Scholar 4 : Screening for prostatic carcinoma with prostate specific antigen. J. Urol., part 21992; 147: 841. Abstract, Google Scholar 5 : Biopsy-proved prostate cancer in 100 consecutive men with benign digital rectal examination and elevated serum prostate-specific antigen level. Prevalence and pathologic characteristics. Urology1993; 42: 150. Google Scholar 6 : Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. II. Radical prostatectomy treated patients. J. Urol.1989; 141: 1076. Link, Google Scholar 7 : Prostate specific antigen in the staging of localized prostate cancer: influence of tumor differentiation, tumor volume and benign hyperplasia. J. Urol.1990; 143: 747. Link, Google Scholar 8 : Combining prostate specific antigen with cancer and gland volume to predict more reliably pathological stage: the influence of prostate specific antigen cancer density. J. Urol.1994; 151: 1565. Link, Google Scholar 9 : PSA-detected (clinical stage T1c or B0) prostate cancer. Pathologically significant tumors. Urol. Clin. N. Amer.1993; 20: 687. Google Scholar 10 : Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. J.A.M.A.1994; 271: 368. Google Scholar 11 : Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J. Urol.1991; 145: 907. Link, Google Scholar 12 : Pathologic differentiation and prognosis of prostatic carcinoma. J.A.M.A.1969; 209: 1701. Google Scholar 13 : Staging of prostate cancer. Sem. Surg. Oncol.1994; 10: 60. Google Scholar 14 : Radical prostatectomy for stage A adenocarcinoma of the prostate: staging errors and their implications for treatment recommendations and disease outcome. J. Urol.1991; 146: 1053. Link, Google Scholar 15 : Stage D1 prostatic adenocarcinoma: significance of nuclear DNA ploidy patterns studied by flow cytometry. Mayo Clin. Proc.1988; 63: 103. Google Scholar 16 : Nonparametric estimation from incomplete observations. J. Amer. Stat. Ass.1958; 53: 457. Google Scholar 17 : Regression models and life-tables. J. Roy. Stat. Soc.1972; 34: 187. Google Scholar 18 : Evaluation of tumor progression by repeated fine needle biopsies in prostate adenocarcinoma: modal deoxyribonucleic acid value and cytological differentiation. J. Urol.1990; 144: 1408. Link, Google Scholar 19 : Analysis of risk factors for progression in patients with pathologically confined prostate cancers after radical retropubic prostatectomy. J. Urol., part 21995; 153: 390A. abstract 648. Google Scholar 20 : Radical prostatectomy for pathologic stage C prostate cancer: influence of pathologic variables and adjuvant treatment on disease outcome. Urology1993; 42: 283. Google Scholar 21 : Relationship of high pre-prostatectomy prostate-specific antigen (PSA) levels to postoperative PSA levels and outcome in prostate cancer (PC). J. Urol., part 21994; 151: 340A. abstract 450. Google Scholar 22 : Ability of preoperative serum prostate-specific antigen value to predict pathologic stage and DNA ploidy. Influence of clinical stage and tumor grade. Urology1993; 41: 207. Google Scholar 23 : Clinical use of prostate specific antigen in patients with prostate cancer. J. Urol.1989; 142: 1011. Link, Google Scholar 24 : Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. J. Urol.1994; 151: 1283. Abstract, Google Scholar 25 : Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. J.A.M.A.1993; 270: 948. Google Scholar 26 : Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. J.A.M.A.1992; 267: 2215. Google Scholar 27 : Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges. J.A.M.A.1993; 270: 860. Google Scholar 28 : Significance of different molecular forms of serum PSA. The free, noncomplexed form of PSA versus that complexed to alpha 1-antichymotrypsin. Urol. Clin. N. Amer.1993; 20: 681. Google Scholar Department of Urology and Section of Biostatistics, Mayo Clinic and Mayo Foundation, Rochester, Minnesota© 1996 by American Urological Association, Inc.FiguresReferencesRelatedDetailsCited byJack G, Cookson M, Coffey C, Vader V, Roberts R, Chang S, Smith J and Shappell S (2018) Pathological Parameters of Radical Prostatectomy for Clinical Stages T1c Versus T2 Prostate Adenocarcinoma: Decreased Pathological Stage and Increased Detection of Transition Zone TumorsJournal of Urology, VOL. 168, NO. 2, (519-524), Online publication date: 1-Aug-2002.EMILIOZZI P, LONGHI S, SCARPONE P, PANSADORO A, DePAULA F and PANSADORO V (2018) THE VALUE OF A SINGLE BIOPSY WITH 12 TRANSPERINEAL CORES FOR DETECTING PROSTATE CANCER IN PATIENTS WITH ELEVATED PROSTATE SPECIFIC ANTIGENJournal of Urology, VOL. 166, NO. 3, (845-850), Online publication date: 1-Sep-2001.HAUTMANN S, CONRAD S, HENKE R, ERBERSDOBLER A, SIMON J, STRAUB M, GRAEFEN M, HAUTMANN R and HULAND H (2018) DETECTION RATE OF HISTOLOGICALLY INSIGNIFICANT PROSTATE CANCER WITH SYSTEMATIC SEXTANT BIOPSIES AND FINE NEEDLE ASPIRATION CYTOLOGYJournal of Urology, VOL. 163, NO. 6, (1734-1738), Online publication date: 1-Jun-2000.TIGUERT R, GHEILER E, GRIGNON D, LITTRUP P, SAKR W, PONTES J and WOOD D (2018) PATIENTS WITH ABNORMAL ULTRASOUND OF THE PROSTATE BUT NORMAL DIGITAL RECTAL EXAMINATION SHOULD BE CLASSIFIED AS HAVING CLINICAL STAGE T2 TUMORSJournal of Urology, VOL. 163, NO. 5, (1486-1490), Online publication date: 1-May-2000.EPSTEIN J, CHAN D, SOKOLL L, WALSH P, COX J, RITTENHOUSE H, WOLFERT R and CARTER H (2018) NONPALPABLE STAGE T1C PROSTATE CANCER: PREDICTION OF INSIGNIFICANT DISEASE USING FREE/TOTAL PROSTATE SPECIFIC ANTIGEN LEVELS AND NEEDLE BIOPSY FINDINGSJournal of Urology, VOL. 160, NO. 6 Part 2, (2407-2411), Online publication date: 1-Dec-1998.LODDING P, AUS G, BERGDAHL S, FROSING R, LILJA H, PIHL C and HUGOSSON J (2018) CHARACTERISTICS OF SCREENING DETECTED PROSTATE CANCER IN MEN 50 TO 66 YEARS OLD WITH 3 TO 4 NG./ML. PROSTATE SPECIFIC ANTIGENJournal of Urology, VOL. 159, NO. 3, (899-903), Online publication date: 1-Mar-1998.Vicini F, Horwitz E, Gonzalez J and Martinez A (2018) Treatment Options for Localized Prostate Cancer Based on Pretreatment Serum Prostate Specific Antigen LevelsJournal of Urology, VOL. 158, NO. 2, (319-325), Online publication date: 1-Aug-1997.Elgamal A, Van Poppel H, Van de Voorde W, Van Dorpe J, Oyen R and Baert L (2018) Impalpable Invisible Stage T1c Prostate Cancer: Characteristics and Clinical Relevance in 100 Radical Prostatectomy Specimens-A Different ViewJournal of Urology, VOL. 157, NO. 1, (244-250), Online publication date: 1-Jan-1997.Eskew L, Bare R and McCullough D (2018) Systematic 5 Region Prostate Biopsy is Superior to Sextant Method for Diagnosing Carcinoma of the ProstateJournal of Urology, VOL. 157, NO. 1, (199-203), Online publication date: 1-Jan-1997.Boccon-Gibod L (2018) Editorial: Significant Versus Insignificant Prostate Cancer—Can We Identify the Tigers from the Pussy Cats?Journal of Urology, VOL. 156, NO. 3, (1069-1070), Online publication date: 1-Sep-1996. Volume 155Issue 3March 1996Page: 821-826 Advertisement Copyright & Permissions© 1996 by American Urological Association, Inc.MetricsAuthor Information Seth E. Lerner Current address: Department of Urology, Albert Einstein College of Medicine, Montefiore Medical Center, 111 East 210th St., Bronx, New York 10467. More articles by this author Thomas M. Seay More articles by this author Michael L. Blute More articles by this author Erik J. Bergstralh More articles by this author David Barrett More articles by this author Horst Zincke More articles by this author Expand All Advertisement PDF downloadLoading ..." @default.
- W2017456906 created "2016-06-24" @default.
- W2017456906 creator A5019283638 @default.
- W2017456906 creator A5038758227 @default.
- W2017456906 creator A5047049480 @default.
- W2017456906 creator A5056962549 @default.
- W2017456906 creator A5058454980 @default.
- W2017456906 creator A5070253773 @default.
- W2017456906 date "1996-03-01" @default.
- W2017456906 modified "2023-10-16" @default.
- W2017456906 title "Prostate Specific Antigen Detected Prostate Cancer (Clinical Stage T1C): An Interim Analysis" @default.
- W2017456906 cites W11097077 @default.
- W2017456906 cites W1535894003 @default.
- W2017456906 cites W195741252 @default.
- W2017456906 cites W1988094389 @default.
- W2017456906 cites W2020160645 @default.
- W2017456906 cites W2084665736 @default.
- W2017456906 cites W2086128695 @default.
- W2017456906 cites W2235954515 @default.
- W2017456906 cites W2335679869 @default.
- W2017456906 cites W2409633540 @default.
- W2017456906 cites W2418785680 @default.
- W2017456906 cites W2431786489 @default.
- W2017456906 cites W2440471858 @default.
- W2017456906 cites W2465273117 @default.
- W2017456906 cites W3041047318 @default.
- W2017456906 cites W4236857774 @default.
- W2017456906 cites W4242246035 @default.
- W2017456906 cites W4242570784 @default.
- W2017456906 cites W4248869731 @default.
- W2017456906 cites W4252086282 @default.
- W2017456906 cites W4255769636 @default.
- W2017456906 cites W4294549545 @default.
- W2017456906 cites W96058809 @default.
- W2017456906 doi "https://doi.org/10.1016/s0022-5347(01)66317-1" @default.
- W2017456906 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/8583584" @default.
- W2017456906 hasPublicationYear "1996" @default.
- W2017456906 type Work @default.
- W2017456906 sameAs 2017456906 @default.
- W2017456906 citedByCount "82" @default.
- W2017456906 countsByYear W20174569062012 @default.
- W2017456906 countsByYear W20174569062013 @default.
- W2017456906 countsByYear W20174569062015 @default.
- W2017456906 countsByYear W20174569062021 @default.
- W2017456906 crossrefType "journal-article" @default.
- W2017456906 hasAuthorship W2017456906A5019283638 @default.
- W2017456906 hasAuthorship W2017456906A5038758227 @default.
- W2017456906 hasAuthorship W2017456906A5047049480 @default.
- W2017456906 hasAuthorship W2017456906A5056962549 @default.
- W2017456906 hasAuthorship W2017456906A5058454980 @default.
- W2017456906 hasAuthorship W2017456906A5070253773 @default.
- W2017456906 hasConcept C121608353 @default.
- W2017456906 hasConcept C126322002 @default.
- W2017456906 hasConcept C126894567 @default.
- W2017456906 hasConcept C143998085 @default.
- W2017456906 hasConcept C146357865 @default.
- W2017456906 hasConcept C151730666 @default.
- W2017456906 hasConcept C166957645 @default.
- W2017456906 hasConcept C2776235491 @default.
- W2017456906 hasConcept C2776957806 @default.
- W2017456906 hasConcept C2780192828 @default.
- W2017456906 hasConcept C2781406297 @default.
- W2017456906 hasConcept C535046627 @default.
- W2017456906 hasConcept C61943457 @default.
- W2017456906 hasConcept C71924100 @default.
- W2017456906 hasConcept C86803240 @default.
- W2017456906 hasConcept C95457728 @default.
- W2017456906 hasConceptScore W2017456906C121608353 @default.
- W2017456906 hasConceptScore W2017456906C126322002 @default.
- W2017456906 hasConceptScore W2017456906C126894567 @default.
- W2017456906 hasConceptScore W2017456906C143998085 @default.
- W2017456906 hasConceptScore W2017456906C146357865 @default.
- W2017456906 hasConceptScore W2017456906C151730666 @default.
- W2017456906 hasConceptScore W2017456906C166957645 @default.
- W2017456906 hasConceptScore W2017456906C2776235491 @default.
- W2017456906 hasConceptScore W2017456906C2776957806 @default.
- W2017456906 hasConceptScore W2017456906C2780192828 @default.
- W2017456906 hasConceptScore W2017456906C2781406297 @default.
- W2017456906 hasConceptScore W2017456906C535046627 @default.
- W2017456906 hasConceptScore W2017456906C61943457 @default.
- W2017456906 hasConceptScore W2017456906C71924100 @default.
- W2017456906 hasConceptScore W2017456906C86803240 @default.
- W2017456906 hasConceptScore W2017456906C95457728 @default.
- W2017456906 hasIssue "3" @default.
- W2017456906 hasLocation W20174569061 @default.
- W2017456906 hasLocation W20174569062 @default.
- W2017456906 hasOpenAccess W2017456906 @default.
- W2017456906 hasPrimaryLocation W20174569061 @default.
- W2017456906 hasRelatedWork W1980188241 @default.
- W2017456906 hasRelatedWork W1992657261 @default.
- W2017456906 hasRelatedWork W2038565121 @default.
- W2017456906 hasRelatedWork W2148869351 @default.
- W2017456906 hasRelatedWork W2373651588 @default.
- W2017456906 hasRelatedWork W2897445903 @default.
- W2017456906 hasRelatedWork W2944341298 @default.
- W2017456906 hasRelatedWork W3129209394 @default.
- W2017456906 hasRelatedWork W3163649103 @default.
- W2017456906 hasRelatedWork W4281788288 @default.